One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Sintx Technologies, Inc.
SINT · NCM · Healthcare · Medical Devices
Current price
$1.88
52-week range
$1.40 - $4.66
Market cap
$12.53M
Balance sheet
Healthy
-206.17x Concerning
Net cash $439.00K. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 30.6% last year.
- Risk Return on equity was -255.9% last year — the company lost money on shareholders' equity.
What this company does
Sintx Technologies, Inc.
Sintx Technologies develops and sells advanced ceramic products, mainly a material called silicon nitride, for use in medical devices like spinal implants. The company's business centers on convincing the medical industry to adopt its unique material because it is strong and has germ-fighting properties, making it a potential replacement for traditional metal or plastic.
How the company got here
Sintx Technologies began its life in 1996 as Amedica Corporation, founded by a surgeon and a scientist to create advanced ceramics for medical use. For years, its main focus was on using a special material called silicon nitride to make spinal fusion implants. A major turning point came in 2018 when the company sold its spine products business and changed its name to Sintx Technologies. This shift allowed it to concentrate on the core science of silicon nitride and explore its use in a wider range of medical and industrial products, moving from just making spine parts to being a broader materials technology company.
What it actually does
At its heart, Sintx is a materials science company that develops and manufactures products from a high-tech ceramic called silicon nitride. Think of it as a super-strong, durable material that has unique properties making it ideal for medical implants because it's compatible with the human body, encourages bone growth, and even helps prevent bacteria from growing on its surface. The company creates this material in different forms, including solid parts for medical devices, powders that can be added to other products, and specialized coatings.
Biomedical & Antipathogenic Applications
This is the company's main business, where it uses its special silicon nitride for medical purposes. It develops and sells its own FDA-cleared medical devices, such as the SiNAPTIC system of implants used in foot and ankle surgery. It also acts as a supplier for other medical companies, for example, by providing the raw material for spinal implants. A key selling point is the material's antipathogenic quality (its ability to inactivate viruses and bacteria), which Sintx is exploring for uses in things like wound dressings and medical equipment coatings to reduce infections.
Industrial Applications
This smaller part of the business takes the same tough silicon nitride ceramic and uses it for non-medical jobs. Because the material is extremely hard and can withstand harsh conditions, it's useful for high-performance parts in industries like aerospace and defense. In this segment, Sintx typically works as a contract manufacturer, meaning other companies hire them to produce specific ceramic components according to their designs. While the company's main focus has shifted to medical devices, this segment still brings in money through purchase orders for these specialized parts.
What management is betting on now
The company's leadership is currently focused on transforming Sintx from a research-oriented company into a business that actively sells its own medical products. Their main bet is on the unique antibacterial and bone-friendly properties of silicon nitride for high-growth medical markets, especially orthopedic (bone-related) surgery. A top priority is commercialization (the process of bringing a product to market and making it profitable) for its FDA-cleared foot and ankle implants by building a network of distributors to sell them to hospitals and surgeons. They are also investing in new technologies like 3D printing to create patient-specific implants.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-2.58M
FY2024 Q4
$-1.27M
FY2025 Q1
$-1.36M
FY2025 Q2
$-2.41M
FY2025 Q3
$-2.60M
FY2025 Q4
$-2.39M
FY2026 Q1
$-2.50M
FY2026 Q2
$-2.85M
Revenue
$452.00K
Net income
$-2.71M
Diluted EPS
-0.75
Operating cash flow
$-2.77M
Free cash flow
$-2.85M
Fetching…
Sources
Revenue
$380.00K
Net income
$-2.82M
Diluted EPS
-0.70
Operating cash flow
$-2.49M
Free cash flow
$-2.50M
Fetching…
Sources
Revenue
$290.00K
Net income
$-2.21M
Diluted EPS
-0.50
Operating cash flow
$-2.34M
Free cash flow
$-2.39M
Fetching…
Sources
Revenue
$208.00K
Net income
$-3.54M
Diluted EPS
-3.46
Operating cash flow
$-2.52M
Free cash flow
$-2.60M
Fetching…
Sources
Revenue
$151.00K
Net income
$-2.32M
Diluted EPS
-0.91
Operating cash flow
$-2.41M
Free cash flow
$-2.41M
Fetching…
Sources
Revenue
$369.00K
Net income
$-2.29M
Diluted EPS
-1.29
Operating cash flow
$-1.30M
Free cash flow
$-1.36M
Fetching…
Sources
Revenue
$542.00K
Net income
$-1.70M
Diluted EPS
-4.51
Operating cash flow
$-1.12M
Free cash flow
$-1.27M
Fetching…
Sources
Revenue
$799.00K
Net income
$-6.24M
Diluted EPS
-6.96
Operating cash flow
$-2.57M
Free cash flow
$-2.58M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.88
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $439,000 - more cash than debt. Interest coverage -206.2x.
Net debt
$-439.00K
Interest coverage
-206.17x
Sintx Technologies, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SINT
BASELINE
Sintx Technologies, Inc.
Total debt $3.15M Interest coverage -206.17x This is the baseline the peer rows are being compared against.
Total debt $26.01M Interest coverage 1.98x This peer still has a real interest-payment cushion, while SINT does not.
Total debt $604.02M Interest coverage -1.26x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SINT
1 Reward
1 Risk
Rewards
-
Revenue grew 30.6% last year.
Risks
-
Return on equity was -255.9% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.45x
P/B
2.58x
P/S
9.42x
EV/EBITDA
-1.07x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
52.9%
Operating margin
-638.5%
Net margin
0.0%
ROE
-255.9%
ROA
-74.2%
Health
Liquidity and balance-sheet strength
Debt / equity
0.65x
Current ratio
2.36x
Quick ratio
1.32x
Total debt
$3.15M
Total cash
$3.59M
Growth
How the business has been compounding
Revenue TTM
$1.33M
Revenue 5Y CAGR
13.8%
EPS TTM
-5.48
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-10.12M
Free CF TTM
$-8.76M
FCF margin
-658.3%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—